ArticleCureus2025
The Efficacy of Dornase Alpha (Polmozyme) in Resolving Persistent Atelectasis in Pediatric Critical Care.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Dornase alpha can be considered an alternative therapy when the standard therapy fails, but evidence of nebulization through artificial airways for persistent pulmonary atelectasis is limited. The study aimed to determine the efficacy of dornase alpha nebulization on persistent atelectasis in non-cystic fibrosis patients with and without artificial airways. Methodology A retrospective cross-sectional study was conducted on patients admitted to the Pediatric Intensive Care Unit (PICU) of King Fahad Medical City (KFMC) between February 2020 and October 2023. The pre- and post-treatment MRAS (Modified Radiologically Assisted Score) was used to determine the treatment efficacy. The independent t-test and chi-square test were used for statistical analysis. Multivariate regression analysis was applied after estimating the propensity score to adjust baseline characteristics to reduce selection and indication bias. A value of p<0.05 was taken to indicate statistical significance. Results Dornase alpha was not an independent positive predictor of MRAS score improvement (B=0.326, p=0.757, Exp(B)=1.385) beyond other variables. However, the dornase group (n = 132) significantly improved the mean MRAS score by 6.08+2.69 compared to the non-dornase group's (n=143) mean MRAS score of 5.14+2.4, with a moderate effect size (Cohen's d=0.364, 95% CI: 0.126 to 0.603; p=0.03) in resolving persistent atelectasis. Conclusion Dornase alpha did not independently improve MRAS scores in pediatric patients with persistent atelectasis, controlling for selection/indication bias and confounding variables. The observed differences in MRAS improvement in the initial analysis were most likely due to baseline differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.